COMMUNIQUÉS West-GlobeNewswire

Kamada Announces Additional Interim Results from Phase 2 Proof of Concept Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection
06/02/2019
Kamada’s IV-AAT demonstrated a trend towards improvements in multiple clinical outcomes, including days on mechanical ventilation post-transplant, pulmonary function at week 4 and week 48 post-transplant and six-minute [...]
BioCryst Strengthens Cash Position With Flexible $100 Million Debt Facility
06/02/2019
—New loan facility increases to $50 million to further extend cash runway— —Additional $30 million available at company option following positive Phase 3 APeX-2 data— —Another $20 million available at company option [...]
IRADIMED CORPORATION Announces Fourth Quarter 2018 Financial Results
06/02/2019
Reports fourth quarter 2018 revenue of $8.3 million Reports fourth quarter 2018 GAAP diluted EPS of $0.14 and non-GAAP diluted EPS of $0.16 Announces 2019 full year and first quarter financial guidance WINTER SPRINGS, [...]
Maverick Technology Solutions Award Winning ROSINBOMB™ Products Now Available Through Walmart
06/02/2019
Inclusion in Mega-Retailers offering Reflective of Product’s Mainstream Appeal and Acceptance. RENO, Nev., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Maverick Technology Solutions (OTC:MVRK), manufacturer of the highly acclaimed [...]
Capricor Resumes Dosing of Enrolled Patients in HOPE-2 Clinical Trial for Duchenne Muscular Dystrophy
06/02/2019
LOS ANGELES, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, today announced that it has resumed per protocol dosing of patients already enrolled in its [...]
Axsome Therapeutics Receives FDA Agreement under Special Protocol Assessment (SPA) for the MOMENTUM Phase 3 Trial of AXS-07 in Migraine
06/02/2019
FDA agreement achieved on Phase 3 trial design, endpoints, and statistical approach Trial to enroll patients with a history of inadequate response to prior migraine treatments Trial initiation anticipated 1Q 2019 NEW [...]
MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab
06/02/2019
Margetuximab improved progression-free survival (PFS) compared to HERCEPTIN® (trastuzumab), when used in combination with chemotherapy in patients with HER2+ metastatic breast cancer BLA submission targeted for second [...]
The Board of Directors of Orion Corporation decided on an incentive plan for key persons
06/02/2019
ORION CORPORATION STOCK EXCHANGE RELEASE 6 FEBRUARY 2019 AT 12.45 PM EET The Board of Directors of Orion Corporation decided on an incentive plan for key persons The Board of Directors of Orion Corporation has decided [...]
Notice to the Annual General Meeting of Orion Corporation
06/02/2019
ORION CORPORATION STOCK EXCHANGE RELEASE 6 FEBRUARY 2019 at 12.30 p.m. EET Notice to the Annual General Meeting of Orion Corporation Notice is given to the shareholders of Orion Corporation to the Annual General Meeting [...]
Orion Group Financial Statement Release for 2018
06/02/2019
ORION CORPORATION FINANCIAL STATEMENT RELEASE 2018 6 FEBRUARY 2019 at 12.00 EET Orion Group Financial Statement Release for 2018 Orion's net sales for continuing operations in 2018 totalled EUR 977 million (EUR 1,034 [...]
Big Health’s New Daylight™ App Combats Worry and Anxiety with Science, Animation and the Power of Voice
06/02/2019
Daylight™ is the first digital therapeutic to combine cognitive behavioral therapy, animation and human voice to help people improve feelings of worry and anxiety Now covering more than 12 million people worldwide, Big [...]
LIDDS employs Head of Clinical Development
06/02/2019
LIDDS has employed Charlotta Gauffin as Head of Clinical Development. Charlotta will join the company in March 2019 and be responsible for the Phase IIb clinical study for Liproca ® Depot and the Phase I study to assess [...]
RECORDATI OBTAINS EXCLUSIVE LICENSE FOR JUXTAPID® IN JAPAN
06/02/2019
RECORDATI OBTAINS EXCLUSIVE LICENSE FOR JUXTAPID® IN JAPAN Milan, 6 February 2019 – Recordati announces the signing of a license agreement with Aegerion Pharmaceuticals Inc., a subsidiary of Novelion Therapeutics Inc., [...]
Reminder: C-RAD Web Presentation Year-end Report 2018
06/02/2019
Presentation of the report for the fiscal year 2018: Date: Friday February 8, 2019 / kl. 13:00 CET Venue: Online Presentation Topic: C-RAD Year-end Report 2018 Procedure: Please register online through the website: [...]
Novelion Therapeutics Subsidiary Enters Into Licensing Agreement for JUXTAPID® in Japan
06/02/2019
Out-licensing of commercialization rights allows for significant operating expense savings Upfront payments improve near-term liquidity VANCOUVER, British Columbia, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Novelion [...]
Aeglea BioTherapeutics Announces Pricing of $60.0 Million Public Offering
06/02/2019
AUSTIN, Texas, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare [...]
Trevena to Present at the 21st Annual BIO CEO & Investor Conference
06/02/2019
CHESTERBROOK, Pa., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment options for patients in pain [...]
Terranueva Grants Options
06/02/2019
MONTRÉAL, Feb. 05, 2019 (GLOBE NEWSWIRE) -- TERRANUEVA CORPORATION (“Terranueva” or the “Company”) announces the grant to its directors, officers, employees and consultants of an aggregate of 2,225,000 stock options to [...]
Terranueva attribue des options
06/02/2019
MONTRÉAL, 05 févr. 2019 (GLOBE NEWSWIRE) -- CORPORATION TERRANUEVA (la « Société » ou « Terranueva ») annonce l’attribution à ses administrateurs, dirigeants, employés et consultants d´un total de 2 225 000 d'options d' [...]

Pages